HES1 and hepatocellular carcinoma: Complementary studies demonstrate that Notch/Hes1 inhibition reduces mTORC1 signaling in gastric cancer (110), while targeting the Hes1/PTEN/AKT/mTOR axis impairs hepatocellular carcinoma progression (111).